Medicare BALANCE Obesity Drug Pilot Collapses
Medicare's BALANCE obesity drug pilot has failed after insurers declined to join, forcing the government to seek alternative GLP-1 coverage paths.
Novo Nordisk
3 articles tagged "Novo Nordisk"
Novo Nordisk Faces Investor Pressure at 2026 Annual Meeting
Novo Nordisk faces shareholder scrutiny as its stock drops 45% since CEO ouster, while rival Eli Lilly surges to a $1 trillion market cap.
FDA Approves High-Dose Wegovy 7.2mg for Obesity in 2026
The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.
By Sarah Tanaka